April 14, 2016 / 10:52 AM / 2 years ago

BRIEF-Oncolytics Biotech reports updated data from Phase 2 study of REOLYSIN

April 14 (Reuters) - Oncolytics Biotech Inc

* Analysis showed a statistically significantly higher percentage of patients surviving two years in test arm versus control arm

* Says at time of data cut off, there were five survivors on study in test arm, and one survivor on study in crossover arm

* Two- and three-year survival for arms may continue to evolve Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below